Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Breast 3Genitourinary 2Gastrointestinal 2

Conditions

Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Pancreatic Neoplasms 5Neoplasms 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Triple Negative Breast Neoplasms 4Melanoma 4Leukemia, Myelomonocytic, Chronic 4Carcinoma, Renal Cell 4Breast Diseases 4Urinary Bladder Neoplasms 3Thoracic Neoplasms 3Respiratory Tract Neoplasms 3Lymphoma 3Lung Diseases 3Leukemia, Myelomonocytic, Acute 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Congenital Abnormalities 3Colonic Neoplasms 3Bronchial Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Uveal Melanoma 2Uterine Cervical Neoplasms 2Sezary Syndrome 2Recurrence 2Rectal Neoplasms 2

Interventions

Carboplatin 9Pemetrexed 7osimertinib 5pembrolizumab 3entinostat 3durvalumab 3Radiosurgery 3Cisplatin 3Bevacizumab 3selpercatinib 2camrelizumab 2Paclitaxel 2Gemcitabine 2Erlotinib Hydrochloride 2Docetaxel 2trametinib 1sotorasib 1repotrectinib 1pralsetinib 1patritumab 1nazartinib 1napabucasin 1icotinib 1exemestane 1cobimetinib 1ceralasertib 1cemiplimab 1capmatinib 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Bronchial Neoplasms × entinostat × Clear all
NCT02897778 2022-04-28

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Syndax Pharmaceuticals

Phase 1 Completed
30 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Digestive System Neoplasms, Endocrine Gland Neoplasms, Kidney Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02909452 2022-01-25

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Syndax Pharmaceuticals

Phase 1 Completed
30 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Diseases, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Digestive System Neoplasms, Endocrine Gland Neoplasms, Kidney Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT01594398 2021-11-19

ENCORE110

Syndax Pharmaceuticals

Phase 1 Completed
14 enrolled
BreastThoracic

Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡